Why is DaVita stock down 3.5% today?

Traders Union
All News
Stocks
DaVita slides 3.51% today on legal woes

Highlights

DaVita faces legal action from the Washington State Attorney General and a separate investor investigation over alleged illegal noncompete agreements with Fresenius.
The company continues to report weak dialysis volumes but projects higher operating income from non-dialysis businesses.
Shares of DaVita fell 3.51% to $177.06, trading below key technical levels with a five-day range of $169.33 to $184.79 and sellers maintaining control.

Investor anxiety climbs as legal actions and business headwinds converge

DaVita has come under legal pressure as Pomerantz LLP announced an investigation on behalf of investors. This was followed by a lawsuit filed by the Washington State Attorney General, accusing DaVita and Fresenius of illegal noncompete agreements that limit doctors and patient care at dialysis centers. The company reported ongoing challenges in dialysis volumes but stated it anticipates higher operating income from its non-dialysis businesses. DaVita continues to operate over 2,600 dialysis centers in the U.S. and maintains a presence in 14 countries globally.

Anton Kharitonov, expert at Traders Union, sees DaVita in a precarious technical position after sharp legal developments. He notes the strong downward momentum, with DVA trading below all major moving averages. Kharitonov points out the risk from ongoing lawsuits and a heavy tone in volume activity. The neutral oscillator readings underscore indecision amid seller dominance. "The combined legal headwinds and persistent technical weakness tell me the downside risk for DaVita remains elevated," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, highlights that the long-term bullish trend is intact despite recent pressure. He maintains confidence in DaVita's ability to leverage its international footprint and rising income from non-dialysis businesses. Karapetjanc emphasizes the broader opportunity to recover if legal overhang fades, especially with volatility creating new setups. "I see potential for renewed upside — the company’s diversification and global scale position DaVita well for further growth," he asserts.

Sholanke Dele, market strategist, remains cautious on DaVita's outlook. He sees renewed regulatory scrutiny as a drag on sentiment and questions investor confidence in the short term. Dele views the current risks as outweighing rewards. "This level of legal exposure gives me little reason to expect a sustained rebound soon," Dele remarks.

Bearish bias persists as price lingers below key moving averages

DaVita is currently trading at $177.06, below its 20-day, 50-day, and 200-day moving averages ($185.54, $182.91, and $180.23 respectively), signaling that sellers are controlling the short-, medium-, and long-term directions. The nearest resistance is at $177.09 and the closest support is at $176.26. The Ichimoku Kijun ($184.1) indicates overhead resistance, and the long-term trend remains bullish. Momentum readings are mixed: the MACD is in strong buy territory, but the ADX shows a neutral trend. All three oscillators (RSI, Stochastic RSI, and CCI) are neutral. Sellers retain a slight edge in intraday momentum, indicated by the Bull/Bear Power reading of -2.2. The price is near the session low with intraday volatility at 2.99%. The overall tone is heavy with little sign of a rebound after the opening decline.

Earlier, analysts noted that DaVita was facing short- and medium-term downside pressure despite a broadly supportive long-term technical structure, with regulatory and legal risks cited as key challenges. The latest legal actions and reinforced technical weakness now heighten downside risk, making $169.33 a critical support level to watch in the coming sessions.

Source of Data: DVA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.